Eighteen patients with metastatic carcinoid were treated by hepatic artery embolization with Gelfoam or polyvinyl alcohol foam for control of the carcinoid syndrome. Seventeen showed subjective or objective clinical improvement, including less skin flushing, diarrhea, and bronchospasm. Fourteen showed improvement in biochemical indices, including decreased urinary 5-hydroxyindoleacetic acid levels. The mean life span of the treated patients from the first episode of flushing to the time of this report was 5.4 years, and half of the patients are still alive. This survival time compares favorably with previous reports of survival of 3.2 years from the onset of flushing.

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiology.155.3.4001362DOI Listing

Publication Analysis

Top Keywords

control carcinoid
8
carcinoid syndrome
8
hepatic artery
8
artery embolization
8
syndrome hepatic
4
embolization eighteen
4
eighteen patients
4
patients metastatic
4
metastatic carcinoid
4
carcinoid treated
4

Similar Publications

A novel molecular classification for small cell lung cancer (SCLC) has been established utilizing the transcription factors achaete-scute homologue 1 (ASCL1), neurogenic differentiation factor 1 (NeuroD1), POU class 2 homeobox 3 (POU2F3), and yes-associated protein 1 (YAP1). This classification was predicated on the transcription factors. Conversely, there is a paucity of information regarding the distribution of these markers in other subtypes of pulmonary neuroendocrine tumors (PNET).

View Article and Find Full Text PDF

Introduction: Choroidal metastases from systemic malignancies are the most common intraocular malignancies in adults. External beam radiation (EBR) has historically been first-line therapy for metastatic tumors to the choroid. However, good responses have been described with newer targeted biologics.

View Article and Find Full Text PDF

Prevalence of second primary malignancies in patients with well-differentiated neuroendocrine tumors.

Endocr Pract

January 2025

Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, 49 Przybyszewskiego Str., 60-355 Poznan, Poland.

Objectives: Neuroendocrine tumors (NETs) constitute a diverse group of tumors. NETs are often diagnosed late, due to nonspecific symptoms. Second Primary Malignancies (SPMs) have been reported in up to 25% of NETs and their incidence has been described as negative predictor of OS.

View Article and Find Full Text PDF

Central nervous system (CNS) metastases of atypical carcinoid tumors are exceptionally rare. Isolated studies suggest a survival benefit in patients who receive whole-brain radiotherapy (WBRT); however, it has been known to have detrimental effects on long-term memory and executive function. Here, we present a case of a patient initially diagnosed with stage IIB bronchopulmonary carcinoid who later developed hepatic and intracranial metastases despite receiving adjuvant systemic therapy over a two-year period.

View Article and Find Full Text PDF

Multinuclear Antimony-Bismuth-Lanthanide Cluster-Connected Polyoxometalate for the Detection of 5-Hydroxyindoleacetic Acid via Luminescence.

Inorg Chem

December 2024

Henan Key Laboratory of Polyoxometalate Chemistry, College of Chemistry and Molecular Sciences, Henan University, Kaifeng, Henan 475004, China.

The judicious selection and combination of multicomponents provide great potential for the further exploration of new polyoxometalate (POM) materials. Here, a delicate control on tungstate, Sb and Bi sources, Eu ions, and organic molecules led to the discovery of a novel multimetal cluster-embedded POM [HN(CH)]NaH{[Eu(HO)SbBiWO](SbWO)(SbWO)}·78HO (). The polyoxoanion of was constructed from four in situ-formed [SbWO] and [SbWO] building blocks connected by two hexa-metallic [Eu(HO)SbBiWO] clusters, to be a rare member of Sb- and Bi-coexisting POM.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!